Raf Van de Plas
Research Subjects
Raf Van de Plas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bart De Moor
KU Leuven
3 shared publications - Etienne Waelkens
Laboratory for Protein Phosphorylation and Proteomics, KU Leuven, O & N1 Herestraat 49, P.O. Box 901, 3000 Leuven, Belgium
3 shared publications - Amelie Fassbender
Department of Development and Regeneration, Woman and Child, KU Leuven, Leuven, Belgium
2 shared publications - Attila Mihalyi
Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium
2 shared publications - Christel Meuleman
Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium
2 shared publications - Cleophas Mutinda Kyama
Department of Medical Laboratory Science, College of Health Sciences, Jomo Kenyatta University of Agriculture & Technology, Nairobi 00100, Kenya
2 shared publications
Latest Publications
- Open Access
- 6 April 2011
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 9 (1) , 44
Erratum to: TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis
- 6 April 2011
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 9 (1) , 44
Open AccessErratum to: TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis
- Open Access
- 21 October 2010
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 8 (1) , 123
TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis
Background: According to mRNA microarray, proteomics and other studies, biological abnormalities of eutopic endometrium (EM) are involved in the pathogenesis of endometriosis, but the relationship between mRNA and protein expression in EM is not clear. We tested for the first time the hypothesis that EM TRIzol extraction allows proteomic Surface Enhanced Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (SELDI-TOF MS) analysis and that these proteomic data can be related to mRNA (microarray) data obtained from the same EM sample from women with and without endometriosis. Methods: Proteomic analysis was performed using SELDI-TOF-MS of TRIzol-extracted EM obtained during secretory phase from patients without endometriosis (n = 6), patients with minimal-mild (n = 5) and with moderate-severe endometriosis (n = 5), classified according to the system of the American Society of Reproductive Medicine. Proteomic data were compared to mRNA microarray data obtained from the same EM samples. Results: In our SELDI-TOF MS study 32 peaks were differentially expressed in endometrium of all women with endometriosis (stages I-IV) compared with all controls during the secretory phase. Comparison of proteomic results with those from microarray revealed no corresponding genes/proteins. Conclusion: TRIzol treatment of secretory phase EM allows combined proteomic and mRNA microarray analysis of the same sample, but comparison between proteomic and microarray data was not evident, probably due to post-translational modifications.
- 21 October 2010
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 8 (1) , 123
Open AccessTRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis
Background: According to mRNA microarray, proteomics and other studies, biological abnormalities of eutopic endometrium (EM) are involved in the pathogenesis of endometriosis, but the relationship between mRNA and protein expression in EM is not clear. We tested for the first time the hypothesis that EM TRIzol extraction allows proteomic Surface Enhanced Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (SELDI-TOF MS) analysis and that these proteomic data can be related to mRNA (microarray) data obtained from the same EM sample from women with and without endometriosis. Methods: Proteomic analysis was performed using SELDI-TOF-MS of TRIzol-extracted EM obtained during secretory phase from patients without endometriosis (n = 6), patients with minimal-mild (n = 5) and with moderate-severe endometriosis (n = 5), classified according to the system of the American Society of Reproductive Medicine. Proteomic data were compared to mRNA microarray data obtained from the same EM samples. Results: In our SELDI-TOF MS study 32 peaks were differentially expressed in endometrium of all women with endometriosis (stages I-IV) compared with all controls during the secretory phase. Comparison of proteomic results with those from microarray revealed no corresponding genes/proteins. Conclusion: TRIzol treatment of secretory phase EM allows combined proteomic and mRNA microarray analysis of the same sample, but comparison between proteomic and microarray data was not evident, probably due to post-translational modifications.
- 1 April 2009
- Vol. 29 (4) , 1039-45
The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
There is a strong need for prognostic biomarkers in ovarian cancer patients due to the heterogeneous responses on current treatment modalities. This study investigates the feasibility of combining laser microdissection (LMD) and surface enhanced laser desorption ionization-time of flight mass spectrometry (SELDI-TOF MS) in ovarian cancer tissue to obtain protein profiles. Ideal conditions for preparing a protein lysate were determined and subsequently analysed on SELDI-TOF MS. Applying these protocols on tissue of 9 ovarian cancer patients showed different protein profiles between platinum sensitive and resistant patients. This shows that combining optimised protocols for LMD with SELDI-TOF MS can be used to obtain discriminatory protein profiles. However, studies with large patient numbers and validation sets are essential to identify reliable biomarkers using this approach.
- 1 April 2009
- Vol. 29 (4) , 1039-45
The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
There is a strong need for prognostic biomarkers in ovarian cancer patients due to the heterogeneous responses on current treatment modalities. This study investigates the feasibility of combining laser microdissection (LMD) and surface enhanced laser desorption ionization-time of flight mass spectrometry (SELDI-TOF MS) in ovarian cancer tissue to obtain protein profiles. Ideal conditions for preparing a protein lysate were determined and subsequently analysed on SELDI-TOF MS. Applying these protocols on tissue of 9 ovarian cancer patients showed different protein profiles between platinum sensitive and resistant patients. This shows that combining optimised protocols for LMD with SELDI-TOF MS can be used to obtain discriminatory protein profiles. However, studies with large patient numbers and validation sets are essential to identify reliable biomarkers using this approach.
- 1 December 2006
- Published by World Scientific Pub Co Pte Ltd
- p. 458-469
PROSPECTIVE EXPLORATION OF BIOCHEMICAL TISSUE COMPOSITION VIA IMAGING MASS SPECTROMETRY GUIDED BY PRINCIPAL COMPONENT ANALYSIS
MALDI-based Imaging Mass Spectrometry (IMS) is an analytical technique that provides the opportunity to study the spatial distribution of biomolecules including proteins and peptides in organic tissue. IMS measures a large collection of mass spectra spread out over an organic tissue section and retains the absolute spatial location of these measurements for analysis and imaging. The classical approach to IMS imaging, producing univariate ion images, is not well suited as a first step in a prospective study where no a priori molecular target mass can be formulated. The main reasons for this are the size and the multivariate nature of IMS data. In this paper we describe the use of principal component analysis as a multivariate pre-analysis tool, to identify the major spatial and mass-related trends in the data and to guide further analysis downstream. First, a conceptual overview of principal component analysis for IMS is given. Then, we demonstrate the approach on an IMS data set collected from a transversal section of the spinal cord of a standard control rat.
- 1 December 2006
- Published by World Scientific Pub Co Pte Ltd
- p. 458-469
PROSPECTIVE EXPLORATION OF BIOCHEMICAL TISSUE COMPOSITION VIA IMAGING MASS SPECTROMETRY GUIDED BY PRINCIPAL COMPONENT ANALYSIS
MALDI-based Imaging Mass Spectrometry (IMS) is an analytical technique that provides the opportunity to study the spatial distribution of biomolecules including proteins and peptides in organic tissue. IMS measures a large collection of mass spectra spread out over an organic tissue section and retains the absolute spatial location of these measurements for analysis and imaging. The classical approach to IMS imaging, producing univariate ion images, is not well suited as a first step in a prospective study where no a priori molecular target mass can be formulated. The main reasons for this are the size and the multivariate nature of IMS data. In this paper we describe the use of principal component analysis as a multivariate pre-analysis tool, to identify the major spatial and mass-related trends in the data and to guide further analysis downstream. First, a conceptual overview of principal component analysis for IMS is given. Then, we demonstrate the approach on an IMS data set collected from a transversal section of the spinal cord of a standard control rat.